Two drugs tested in adults and children with a BRAF V600 gene change
Original title: DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a later stage trial, but the drugs are still being tested for these cancers.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests if two known cancer drugs help more cancers that share one gene change.
Who this trial is for. This trial is for adults, teens, young adults, and children. It tests two drugs, dabrafenib and trametinib, in cancers with a BRAF V600 change.
Where it stands. This trial has not reported results. It is looking at whether these two drugs help other cancer types that have the same gene change. The answer is not in yet.
What this means, and what it doesn't
What it could mean: These two drugs are already approved for some cancers. Those include melanoma, lung cancer, and glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary in children. This trial asks if they also help other cancers with a BRAF V600 change. The study team says that if the results are good, they will work with the NHS to see if more patients can get these drugs. If your cancer has a BRAF V600 change, you could ask your care team about this trial.
What it doesn't mean: This does not mean these drugs work for other cancers. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that it will help you. It is not a promise of a cure. The trial team decides who can take part, not us.
Source: ClinicalTrials.gov, August 17, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.